Talk to your healthcare provider about your medical history before starting semaglutide treatment, as certain health conditions may increase your risk of experiencing serious side effects
Contraindications Do Not Use If You Have known hypersensitivity to NAD+ or any ingredient in the formulation Have active skin infection, open wounds, or severe skin conditions on the application area Warnings and Precautions Patch test first: Apply a small amount to an inconspicuous area and wait 24 hours before full-face application Avoid contact with eyes, mucous membranes, and broken skin Sun sensitivity: Use sunscreen during daytime use as retinoid-adjacent ingredients may increase photosensitivity Discontinue use and contact your provider if persistent irritation, burning, or rash occurs Common Side Effects Temporary redness or mild stinging on application Skin dryness or flaking Mild irritation, especially during first weeks of use Use in Pregnancy and Breastfeeding Safety during pregnancy and breastfeeding has not been established
Published online 2025
In June 2021, the FDA approved Semaglutide (Wegovy), a GLP-1 receptor agonist developed by Novo Nordisk, for use as a weight loss drug
Over-the-counter (OTC) pain relievers: OTC pain relievers such as acetaminophen or ibuprofen can helpreduceheadache pain
